Navigation Links
New Insights into the Mechanism of Action of Antipsychotic Drugs
Date:3/10/2009

lease visit http://www.vandapharma.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failure to become or remain profitable; Vanda's inability to obtain the capital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the quarter ended September 30, 2008 (Fil
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PAREXEL Experts to Present Leading Insights at Drug Information Association 21st Annual Euromeeting
2. New Study Shares Insights for Competitive Intelligence Policies, Ethics and Data Collection
3. Museomics yields new insights into extinct Tasmanian tiger
4. Jatropha Sector Reality Check: Still Viable In Volatile Times? Upcoming Webcast Shares Latest Insights
5. European Nephrologists Share Insights on the Management of Renal Anemia and Hyperphosphatemia in Latest BioTrends Report
6. Protein Research Marketing Insights
7. Microsurgery on the brain of the fruit fly leads to new insights into irreparable nerve injuries
8. Peripheral Vascular Device Market Insights Webinar
9. New insights into cellular reprogramming revealed by genomic analysis
10. Pharmaceuticals & Biotechs to Share Insights for Developing Leaders in a Fast-Paced, Competitive Industry
11. PAREXEL Experts to Offer Insights Into Outsourcing Best Practices at 17th Annual Partnerships with CROs Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... GUELPH, ON , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. ... the three and six-month periods ended June 30, 2015. Biorem,s complete ... ( www.sedar.com ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per ... , 2014 , 2015 , ... 9,398 , 4,433 Gross profit , 1,656 ...
(Date:8/27/2015)... ... 27, 2015 , ... METTLER TOLEDO's web-based EasyFinder™ ... choices to a manageable shortlist of bench and floor scales and terminals. Specifying ... best with the customer’s industry and application. , Side-by-side product comparisons and ...
(Date:8/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended June 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... our Oral Amp B program, rapidly advancing towards ... Andrew Rae , President & CEO of iCo ...
(Date:8/26/2015)... FRANCISCO , Aug. 26, 2015  Platform ... that it has received a $1.5M Phase II ... (NIH) to further develop its therapeutic agent to ... clinical need in end stage renal disease (ESRD) ... the National Institute of Diabetes and Digestive and ...
Breaking Biology Technology:BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3METTLER TOLEDO Updates Online Scale Selection Tool 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... Feb. 9, 2011 Selexis SA , a ... engineering of high yield and stable mammalian cell-lines for ... the company,s Swiss-based laboratories and staff.  The additional space ... recombinant therapeutic proteins as well as outsourcing support for ...
... HIGHLIGHTS:2010 Results (all percentages are to comparable ... were $582 million, a new quarterly high. Q4 sales grew by ...  Full year 2010 sales increased 6% and 5% on a reported ... reported diluted EPS was $0.76. Excluding restructuring costs of $0.07, adjusted ...
... NEW YORK, Feb. 9, 2011 Reportlinker.com announces ... in its catalogue: Strategic Analysis ... http://www.reportlinker.com/p0376721/Strategic-Analysis-of-European-Human-Machine-Interface-HMI-Market.html This ... for Europe primarily over the two broad categories ...
Cached Biology Technology:Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 3Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 4Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 5Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 6Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 7Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 8Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 9Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 10Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 11Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 12Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be 13Reportlinker Adds Strategic Analysis of European Human Machine Interface (HMI) Market 2
(Date:8/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... Alliance and the EMV Migration Forum.  ... Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. direct ... promoting adoption of smart card technology. To ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
(Date:8/17/2015)... , Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... sales campaign for Q4 2015. The new marketing campaign ... consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and ... is a leader in retail driven marketing and brand ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3
... mountain meadows in the Pacific Northwest are declining rapidly due ... growing seasons and other factors allow trees to invade these ... wildflowers. The process appears to have been going on ... Jefferson Park, a subalpine meadow complex in the central Oregon ...
... Planck Institute for Chemical Energy Conversion (MPI CEC) and ... on a hydrogen-producing enzyme that the environment of the ... enzyme. Thus, it can very efficiently produce hydrogen, which ... research team describes their results in the journal " ...
... Calif.During the early developmental stages of vertebratesanimals that ... undergo extensive rearrangements, and some cells migrate over ... novel roles as differentiated cell types. Understanding how ... an embryo is an important and complex goal ...
Cached Biology News:Mountain meadows dwindling in the Pacific Northwest 2Temporary storage for electrons: Natural method of producing hydrogen 2Developmental bait and switch 2Developmental bait and switch 3
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... (5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside) is a chromogenic ... recombinant plasmids. In the ... IPTG, lac + ... whereas recombinant colonies appear ...
... refrigerated multifunction centrifuges are equally capable of high ... sound level with a large range of rotors ... exchange system without tools ensures that the required ... Instant rotor exchange (5 sec.) with ...
... SuperScript™ III RNase H- ... an improved version of ... RT. Like SuperScript™ II ... DNA strand from single-stranded ...
Biology Products: